🇺🇸 FDA
Patent

US 10420773

Methods of treating developmental disorders and/or seizure disorders with etifoxine

granted A61KA61K31/536A61P

Quick answer

US patent 10420773 (Methods of treating developmental disorders and/or seizure disorders with etifoxine) held by OVID THERAPEUTICS INC. expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OVID THERAPEUTICS INC.
Grant date
Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/536, A61P, A61P25/00, A61P25/22